<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805047</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2020LSK-073</org_study_id>
    <nct_id>NCT04805047</nct_id>
  </id_info>
  <brief_title>SodiUm Restriction by Behavioral Intervention</brief_title>
  <acronym>SURBI</acronym>
  <official_title>Sodium Restriction by Behavioral Intervention: Education and Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effects and efficacy of dietary sodium restriction&#xD;
      by mean of a new healthcare approach in patients with immunoglobulin A nephropathy. The test&#xD;
      persons in the intervention group are actively supported to adhere to a restricted sodium&#xD;
      diet with a structured education program in combination with regular sodium excretion&#xD;
      monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in the intervention group receive regular sodium-restriction education by a&#xD;
      dietician, which entails introducing food types and cooking skills, quantifying salt intake&#xD;
      with a special spoon and recording detailed interactive food diary. Sodium excretion was&#xD;
      measured using one 24-hour urine collection regularly to assess dietary compliance and enable&#xD;
      feedback. The test persons with sodium excretion higher than 90mmol/24h will receive&#xD;
      intensive education. Test persons in the control group receive standard care. After 2 weeks&#xD;
      in study, all test persons visit the outpatient clinic for measurements and data collection.&#xD;
      Within 3 months of total study duration, data collection and measurements take place at the&#xD;
      end of every month.&#xD;
&#xD;
      At each timepoint blood and 24-hourly urine is collected, test persons fill out&#xD;
      questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour urine protein excretion</measure>
    <time_frame>3 months</time_frame>
    <description>24 hour urine protein excretion after 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hour urine sodium excretion</measure>
    <time_frame>3 months</time_frame>
    <description>24 hour urine sodium excretion after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>blood pressure after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated Glomerular Filtration Rate change</measure>
    <time_frame>3 months</time_frame>
    <description>estimated Glomerular Filtration Rate change after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological well-being</measure>
    <time_frame>3months</time_frame>
    <description>Psychological well-being will be assessed with multiple choice questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Intervention:education and monitoring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>regular care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>education and monitoring</intervention_name>
    <description>regular education programs supported by a dietician in combination with urine sodium monitoring as a feedback</description>
    <arm_group_label>Intervention:education and monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patients&gt;14 years of age and &lt;70 years of age&#xD;
&#xD;
          -  Diagnosed immunoglobulin A nephropathy with biopsy;&#xD;
&#xD;
          -  eGFR&gt;30ml/min per 1.73m2 using Chronic Kidney Disease Epidemiology Collaboration&#xD;
             formula&#xD;
&#xD;
          -  Proteinuria &gt;1 g per day&#xD;
&#xD;
          -  urinary sodium excretion &gt;200 mmol per day within one month&#xD;
&#xD;
          -  systolic blood pressure higher than 140 mmHg or diastolic blood pressure higher than&#xD;
             90 mmHg, or a well-controlled blood pressure by treatment with antihypertensives&#xD;
             including renin-angiotensin-aldosterone system-blockade (ACE-inhibitor or ARB)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Be treated with diuretics&#xD;
&#xD;
          -  Blood pressure &gt; 180 mmHg systolic or &gt; 125 mmHg diastolic without medical treatment&#xD;
&#xD;
          -  Have undergone renal transplantation&#xD;
&#xD;
          -  With acute kidney injury (RIFLE criteria) &lt; 6 months ago&#xD;
&#xD;
          -  Cardiovascular or cerebrovascular event (myocardial infarction, cerebral hemorrhage or&#xD;
             infarction) &lt; 6 months ago&#xD;
&#xD;
          -  With progressive malignancy or pregnancy&#xD;
&#xD;
          -  With contraindications of RAAS blockers&#xD;
&#xD;
          -  unwilling or unable to meet the requirements of the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huixian Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huixian Li</last_name>
    <phone>17792905602</phone>
    <phone_ext>17792905602</phone_ext>
    <email>lihuixian_muye@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First affiliated hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huixian Li, Master</last_name>
      <phone>18691636705</phone>
      <email>lihuixian_muye@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

